Search

Displaying results 9231 - 9240 of 9689 in total
  1. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … The compound is known as a direct acting antiviral (DAA) for coronaviruses, and was initially developed using structure-guided design to combat MERS-Cov infections[A219036,A219056].

  2. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity of the vaccine. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.

  3. Drug

    Dendritic cells vaccine

    go.drugbank.com/drugs/DB15803
    Investigational

    The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. … With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity

  4. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    a productive infection in humans. … (Fractions A and C from _Quillaja saponaria_ extract).

  5. Drug

    V-SARS

    go.drugbank.com/drugs/DB15812
    Investigational

    This therapeutic concept was applied to the development of V-SARS, which heat inactivates the plasma, and packages it into a once-daily pill form. … Immunitor Inc., the sponsor, is currently testing this oral vaccine for immunogenicity in 20 healthy volunteers in a Phase 1 clinical trial (NCT04380532).

  6. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    or a novel TLR7/8 agonist adsorbed gel. … The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel)

  7. Drug

    MVC-COV1901

    go.drugbank.com/drugs/DB15854
    Investigational

    MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein.

  8. Drug

    NasoVAX

    go.drugbank.com/drugs/DB15859
    Investigational

    It is a vaccine administered through a nasal spray that expresses influenza hemagglutinin in nasal epithelial cells[L16313]. … As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230).

  9. Drug

    Inactivated SARS-Cov-2 Vaccine

    go.drugbank.com/drugs/DB15862
    Investigational

    This strain was isolated from a patient in Wuhan, cultivated in a Vero cell line, and then subsequently inactivated using B-propiolactone.

  10. Drug

    Probiorinse

    go.drugbank.com/drugs/DB15870
    Experimental

    Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.